Akari Therapeutics, Plc Operating Income
Akari Therapeutics, Plc (AKTX) reported Operating Income of -$4.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-13
- Akari Therapeutics, Plc operating income (loss) for the quarter ending 2026-06-30 was -$4.60M.
- Akari Therapeutics, Plc operating income (loss) for the quarter ending 2026-03-31 was -$15.76M.
- Akari Therapeutics, Plc operating income (loss) for the quarter ending 2025-12-31 was -$3.23M.
- Akari Therapeutics, Plc operating income (loss) for the quarter ending 2025-09-30 was -$7.40M.
- Akari Therapeutics, Plc operating income (loss) for fiscal 2025 was -$17.27M.
- Akari Therapeutics, Plc operating income (loss) for fiscal 2024 was -$21.64M.
- Akari Therapeutics, Plc operating income (loss) for fiscal 2023 was -$16.81M.
- Akari Therapeutics, Plc operating income (loss) for fiscal 2013 was -$3.61M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 12 month | Operating Income (Loss) 12 month as first filed | Operating Income (Loss) 99 month | Operating Income (Loss) 111 month |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$4.60M 10-Q · filed 2026-08-13 | -$20.36M 10-Q · filed 2026-08-13 | -$23.59M derived: sum of 3 quarters · filed 2026-08-13 | -$30.99M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2026-03-31 | -$15.76M 10-Q · filed 2026-05-19 | -$18.98M derived: sum of 2 quarters · filed 2026-05-19 | -$26.39M derived: sum of 3 quarters · filed 2026-05-19 | -$29.51M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-12-31 | -$3.23M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$10.63M derived: sum of 2 quarters · filed 2026-03-30 | -$13.75M derived: sum of 3 quarters · filed 2026-08-13 | -$17.27M 10-K · filed 2026-03-30 | |||||
| 2025-09-30 | -$7.40M 10-Q · filed 2025-11-13 | -$10.52M derived: sum of 2 quarters · filed 2026-08-13 | -$14.05M 10-Q · filed 2025-11-13 | -$19.33M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-06-30 | -$3.12M 10-Q · filed 2026-08-13 | -$6.64M 10-Q · filed 2026-08-13 | -$11.92M derived: sum of 3 quarters · filed 2026-08-13 | -$14.85M derived: sum of 4 quarters · filed 2026-08-13 | |||||
| 2025-03-31 | -$3.52M 10-Q · filed 2026-05-19 | -$8.80M derived: sum of 2 quarters · filed 2026-05-19 | -$11.73M derived: sum of 3 quarters · filed 2026-05-19 | -$19.18M derived: sum of 4 quarters · filed 2026-05-19 | |||||
| 2024-12-31 | -$5.28M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-30 | -$8.21M derived: sum of 2 quarters · filed 2026-03-30 | -$15.65M derived: sum of 3 quarters · filed 2026-03-30 | -$21.64M 10-K · filed 2026-03-30 | |||||
| 2024-09-30 | -$2.93M 10-Q · filed 2025-11-13 | -$10.38M derived: sum of 2 quarters · filed 2025-11-13 | -$16.36M 10-Q · filed 2025-11-13 | -$21.45M derived: sum of 4 quarters · filed 2025-11-13 | |||||
| 2024-06-30 | -$7.45M 10-Q · filed 2025-08-13 | -$13.44M 10-Q · filed 2025-08-13 | -$18.53M derived: sum of 3 quarters · filed 2025-08-13 | -$21.04M derived: sum of 4 quarters · filed 2025-08-13 | |||||
| 2024-03-31 | -$5.99M 10-Q · filed 2025-05-14 | -$11.08M derived: sum of 2 quarters · filed 2025-05-14 | -$13.59M derived: sum of 3 quarters · filed 2025-05-14 | -$16.26M derived: sum of 4 quarters · filed 2025-05-14 | |||||
| 2023-12-31 | -$5.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-15 | -$7.60M derived: sum of 2 quarters · filed 2025-04-15 | -$10.27M derived: sum of 3 quarters · filed 2025-04-15 | -$16.81M 10-K · filed 2025-04-15 | |||||
| 2023-09-30 | -$2.51M 10-Q · filed 2024-11-19 | -$5.18M derived: sum of 2 quarters · filed 2024-11-19 | -$11.72M 10-Q · filed 2024-11-19 | ||||||
| 2023-06-30 | -$2.67M 8-K · filed 2024-09-06 | -$4.62M 10-Q · filed 2024-08-19 | -$9.89M 8-K · filed 2024-09-06 | -$9.21M 6-K · filed 2023-09-29 | |||||
| 2023-03-31 | -$4.59M 10-Q · filed 2024-05-15 | ||||||||
| 2022-12-31 | -$11.85M 8-K · filed 2024-09-06 | -$23.09M 20-F · filed 2023-05-01 | |||||||
| 2022-06-30 | -$5.82M 6-K · filed 2022-09-27 | -$11.06M 6-K · filed 2023-09-29 | |||||||
| 2021-12-31 | -$17.21M 20-F · filed 2023-05-01 | ||||||||
| 2021-06-30 | -$4.33M 6-K · filed 2022-09-27 | -$9.88M 6-K · filed 2022-09-27 | |||||||
| 2020-12-31 | -$6.90M derived: 20-F 12 month − 20-F 9 month · filed 2023-05-01 | -$7.14M derived: sum of 2 quarters · filed 2023-05-01 | -$13.05M derived: sum of 3 quarters · filed 2023-05-01 | -$17.98M 20-F · filed 2023-05-01 | |||||
| 2020-09-30 | -$246.88K 20-F · filed 2021-04-21 | -$6.16M derived: sum of 2 quarters · filed 2021-09-22 | -$11.09M 20-F · filed 2021-04-21 | -$18.91M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-06-30 | -$5.91M 6-K · filed 2021-09-22 | -$10.84M 6-K · filed 2021-09-22 | -$18.66M derived: sum of 3 quarters · filed 2022-05-16 | -$21.78M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2020-03-31 | -$4.93M 20-F · filed 2021-04-21 | -$12.75M derived: sum of 2 quarters · filed 2022-05-16 | -$15.87M derived: sum of 3 quarters · filed 2022-05-16 | -$21.90M derived: sum of 4 quarters · filed 2022-05-16 | |||||
| 2019-12-31 | -$7.83M derived: 20-F 12 month − 20-F 9 month · filed 2022-05-16 | -$10.94M derived: sum of 2 quarters · filed 2022-05-16 | -$16.98M derived: sum of 3 quarters · filed 2022-05-16 | -$16.96M 20-F · filed 2022-05-16 | |||||
| 2019-09-30 | -$3.12M 20-F · filed 2021-04-21 | -$9.15M derived: sum of 2 quarters · filed 2021-04-21 | -$9.14M 20-F · filed 2021-04-21 | ||||||
| 2019-06-30 | -$6.03M 20-F · filed 2021-04-21 | -$6.02M 20-F · filed 2021-04-21 | |||||||
| 2019-03-31 | $11.96K 20-F · filed 2021-04-21 | ||||||||
| 2018-12-31 | -$20.79M 20-F · filed 2021-04-21 | -$19.99M 20-F · filed 2019-04-23 | |||||||
| 2018-06-30 | -$7.98M 6-K · filed 2019-08-29 | -$12.28M 6-K · filed 2019-08-29 | |||||||
| 2017-12-31 | -$37.78M 20-F · filed 2020-03-31 | ||||||||
| 2017-06-30 | -$7.35M 6-K · filed 2018-09-27 | -$15.63M 6-K · filed 2018-09-27 | |||||||
| 2016-12-31 | -$27.25M 20-F · filed 2019-04-23 | ||||||||
| 2016-06-30 | -$7.52M 6-K · filed 2017-08-10 | -$11.37M 6-K · filed 2017-08-10 | -$15.66M derived: sum of 3 quarters · filed 2018-07-18 | -$38.99M derived: sum of 4 quarters · filed 2018-07-18 | |||||
| 2016-03-31 | -$3.85M 10-Q · filed 2016-05-12 | -$8.14M derived: sum of 2 quarters · filed 2018-07-18 | -$31.47M derived: sum of 3 quarters · filed 2018-07-18 | -$32.78M derived: sum of 4 quarters · filed 2018-07-18 | |||||
| 2015-12-31 | -$4.29M derived: 20-F 12 month − 10-Q 9 month · filed 2018-07-18 | -$27.62M derived: sum of 2 quarters · filed 2018-07-18 | -$28.93M derived: sum of 3 quarters · filed 2018-07-18 | -$30.58M 20-F · filed 2018-07-18 | |||||
| 2015-09-30 | -$23.33M 10-Q · filed 2015-11-23 | -$24.64M derived: sum of 2 quarters · filed 2017-04-14 | -$26.29M 10-Q · filed 2015-11-23 | -$27.40M derived: sum of 4 quarters · filed 2017-04-14 | |||||
| 2015-06-30 | -$1.31M 6-K · filed 2017-04-14 | -$1.46M 10-Q · filed 2015-08-12 | -$2.97M 6-K · filed 2017-04-14 | -$3.80M 10-Q · filed 2015-08-12 | -$4.07M derived: sum of 3 quarters · filed 2017-04-14 | -$4.29M derived: sum of 4 quarters · filed 2017-04-14 | |||
| 2015-03-31 | -$1.65M 10-Q · filed 2016-05-12 | -$2.34M 10-Q · filed 2015-05-12 | -$2.76M derived: sum of 2 quarters · filed 2017-03-31 | -$2.98M derived: sum of 3 quarters · filed 2017-03-31 | -$5.31M derived: sum of 4 quarters · filed 2017-03-31 | ||||
| 2014-12-31 | -$1.11M derived: 20-F 12 month − 10-Q 9 month · filed 2017-03-31 | -$1.32M derived: sum of 2 quarters · filed 2017-03-31 | -$3.65M derived: sum of 3 quarters · filed 2017-03-31 | -$1.92M 20-F · filed 2017-03-31 | -$10.18M 10-K · filed 2015-02-11 | ||||
| 2014-09-30 | -$218.03K 10-Q · filed 2015-11-23 | -$2.55M derived: sum of 2 quarters · filed 2015-11-23 | -$814.16K 10-Q · filed 2015-11-23 | ||||||
| 2014-06-30 | -$2.33M 10-Q · filed 2015-08-12 | -$4.21M 10-Q · filed 2015-08-12 | |||||||
| 2014-03-31 | -$1.88M 10-Q · filed 2015-05-12 | ||||||||
| 2013-12-31 | -$3.61M 10-K · filed 2015-02-11 | -$17.29M 20-F · filed 2014-03-24 | |||||||
| 2012-12-31 | -$3.67M 10-K · filed 2015-02-11 | -$13.68M 20-F/A · filed 2013-04-19 | |||||||
| 2011-12-31 | -$2.25M 20-F · filed 2014-03-24 | ||||||||
| 2010-12-31 | -$792.00K 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |